Christophe Weber, Takeda CEO Shoko TakayasuNovember 9, 2023FDA approves Takeda’s new enzyme replacement therapy for rare blood clotting disorderZachary BrennanSenior EditorThe FDA on Thursday approved Takeda’s Adzynma, an enzyme replacement therapy for adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), which is a rare and potentially fatal blood clotting disorder. The approval was...